Ultragenyx Pharmaceutical

RARE

Market cap $2.27B

NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Ultragenyx Pharmaceutical Inc. ("Ultragenyx Pharmaceutical Inc.") (NASDAQ: RARE) concerning potential violations of the federal securities laws. What Happened?

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980.

Ultragenyx Pharmaceutical Inc. (RARE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Preliminary 2025 total revenue of $672 million to $674 million, exceeding top end of guidance  Preliminary cash and investments of approximately $735 million as of December 31, 2025 Anticipated 2026 catalysts include two potential approvals and pivotal Phase 3 data from the GTX-102 Phase 3 Aspire study for Angelman syndrome

NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext.

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980.

Ultragenyx jumps after completing rolling BLA submission to the FDA for DTX401, an AAV gene therapy that could become the first approved treatment for GSDIa.

Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980.